SGX945's Phase 2a Behçet's endpoint gives SNGX a post-HyBryte pivot candidate — survival to Phase 2b data is the test

Soligenix is a clinical-stage biopharmaceutical company developing an innate defense regulator for Behçet's disease, a rare inflammatory condition causing oral and genital ulcers, which is not yet approved.

SGX945 (dusquetide) is an IV-formulated innate defense regulator targeting oral and genital ulcers in Behçet's Disease, a rare inflammatory condition with limited approved therapies. The thesis turns on whether a reformulated, home-compatible version advances through a Phase 2b placebo-controlled study and replicates the Phase 2a biological efficacy signal in a larger, registrational-quality trial. The primary risks are an $6M cash position that almost certainly cannot fund a Phase 2b trial without dilutive financing, and competition from apremilast, which has already demonstrated Phase 3 efficacy in Behçet's oral ulcers and sets a high clinical comparator bar.